In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Performance of ETFE-Coated Components for Container Closure Integrity
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations

PFS and Autoinjector Drug Delivery: A Platform of Primary Packaging Solutions for Str...
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Aptar Pharma Expands Injectables Components Manufacturing Capabilities
Publications, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Characterizing and Controlling Foreign Particulate Matters (FPM)
Webinars, Pharmaceutical, Product Solutions, Market Insights